Anti-TOMM20 antibody [EPR15581-54] - Mitochondrial Marker (Ab186735)

Anti-TOMM20 antibody [EPR15581-54] - Mitochondrial Marker (ab186735) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-Fr, IHC-P and WB. Anti-TOMM20 antibody [EPR15581-54] - Mitochondrial Marker (ab186735) was first used in a scientific publication in 2017 and has been cited over 161 times in peer reviewed journals. It's performance in Western Blot in human and mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-TOMM20 antibody [EPR15581-54] - Mitochondrial Marker (ab186735) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-TOMM20 antibody [EPR15581-54] - Mitochondrial Marker (ab186735) has 8 independent reviews from customers. Anti-TOMM20 antibody [EPR15581-54] - Mitochondrial Marker (ab186735) specifically detects TOMM20 (UniProt ID: Q15388; Molecular weight: 17kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR15581-54 - ab232589. Antibody clone EPR15581-54 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, HRP, Alexa Fluor ® 405, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555, APC, PE, Alexa Fluor ® 488 ( ab209606, ab209951, ab210047, ab210665, ab210841, ab221292, ab225341, ab225342, ab320072 ). TOMM20 is a key protein in neuro research, particularly for its role in mitochondrial function and health. It is part of the translocase of the outer mitochondrial membrane complex, essential for importing proteins into mitochondria. Researchers use TOMM20 to study mitochondrial dynamics, biogenesis and mitophagy, making it vital for understanding cellular energy metabolism and neurodegenerative diseases. Its expression helps in assessing mitochondrial integrity and function in various neurological conditions. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.